The schedule adopted in this study involved three intraperitoneal administrations of anti-PD-1 on days 3, 6, and 9 following the subcutaneous implantation of CT26 tumors, which resulted in a variable impact on the tumor growth rate during early tumor development and a 20%–30% curative response rate (figure 1A). Here, PDCD1 is linked to neoplasm.